Rare instances of acute pancreatitis and acute liver injury induced by dapagliflozin tablets:one case report
As one of sodium-glucose cotransporter 2 inhibitors(SGLT2i),dagliflozin was the first SGLT2i agent approved for treating type 2 diabetes mellitus(T2DM)in EU in 2012 and later in China in 2017.In addition to its definite hypoglycemic effect,it has demonstrated promising efficacies for heart failure and chronic kidney disease in China.With its widespread clinical applications,many adverse reactions have been reported.Acute pancreatitis was mentioned in a foreign report.Only one case of acute liver injury was reported glob-ally.Here we described one case of acute pancreatitis and acute liver injury caused by dagliflozin.
dapagliflozinacute pancreatitisacute liver injuryadverse drug reaction
NETL
NSTL
万方数据
